KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Payables: 2018-2024

Historic Payables for Adaptive Biotechnologies (ADPT) over the last 7 years, with Dec 2024 value amounting to $7.3 million.

  • Adaptive Biotechnologies' Payables rose 39.67% to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.8 million, marking a year-over-year decrease of 16.99%. This contributed to the annual value of $7.3 million for FY2024, which is 5.88% down from last year.
  • Adaptive Biotechnologies' Payables amounted to $7.3 million in FY2024, which was down 5.88% from $7.7 million recorded in FY2023.
  • Adaptive Biotechnologies' Payables' 5-year high stood at $8.1 million during FY2022, with a 5-year trough of $3.2 million in FY2020.
  • In the last 3 years, Adaptive Biotechnologies' Payables had a median value of $7.7 million in 2023 and averaged $7.7 million.
  • As far as peak fluctuations go, Adaptive Biotechnologies' Payables declined by 27.31% in 2020, and later soared by 144.45% in 2022.
  • Yearly analysis of 5 years shows Adaptive Biotechnologies' Payables stood at $3.2 million in 2020, then climbed by 2.16% to $3.3 million in 2021, then surged by 144.45% to $8.1 million in 2022, then declined by 4.52% to $7.7 million in 2023, then declined by 5.88% to $7.3 million in 2024.